371 related articles for article (PubMed ID: 8744073)
1. [Sotalol and torsades de pointes ventricular tachycardia].
Petersen HH; Sandøe E
Ugeskr Laeger; 1996 May; 158(19):2711-6. PubMed ID: 8744073
[TBL] [Abstract][Full Text] [Related]
2. [Torsade de Pointes tachycardia during sotalol treatment of a patient with normal potassium levels].
Appel JM; Sigurd B
Ugeskr Laeger; 1996 Jul; 158(28):4093-4. PubMed ID: 8701528
[TBL] [Abstract][Full Text] [Related]
3. A case series of drug-induced long QT syndrome and Torsade de Pointes.
Tong KL; Lau YS; Teo WS
Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
[TBL] [Abstract][Full Text] [Related]
4. [Sotalol-induced torsade de pointes tachycardia in a 15-month-old infant].
Sasse M; Paul T; Bergmann P; Kallfelz HC
Z Kardiol; 1995 Oct; 84(10):863-6. PubMed ID: 7502575
[TBL] [Abstract][Full Text] [Related]
5. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
Skanes AC; Morton BC; Green MS; Tang AS
Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
[TBL] [Abstract][Full Text] [Related]
6. [Sotalol--atrial fibrillation, reduced renal function and sudden death].
Bathen J; Madsen S
Tidsskr Nor Laegeforen; 1998 Oct; 118(26):4086-7. PubMed ID: 9844513
[TBL] [Abstract][Full Text] [Related]
7. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
[TBL] [Abstract][Full Text] [Related]
8. Sotalol-induced torsades de pointes in patients with renal failure.
Dancey D; Wulffhart Z; McEwan P
Can J Cardiol; 1997 Jan; 13(1):55-8. PubMed ID: 9039065
[TBL] [Abstract][Full Text] [Related]
9. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs.
Thomsen MB; Verduyn SC; Stengl M; Beekman JD; de Pater G; van Opstal J; Volders PG; Vos MA
Circulation; 2004 Oct; 110(16):2453-9. PubMed ID: 15477402
[TBL] [Abstract][Full Text] [Related]
10. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
Shah SA; Kluger J; White CM
Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
[TBL] [Abstract][Full Text] [Related]
11. Clinical study of amiodarone-associated torsade de pointes in Chinese people.
Geng DF; Jin DM; Wang JF; Luo YJ; Wu W
Pacing Clin Electrophysiol; 2006 Jul; 29(7):712-8. PubMed ID: 16884506
[TBL] [Abstract][Full Text] [Related]
12. Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease.
D'Aloia A; Faggiano P; Brentana L; Boldini A; Pedrinazzi C; Procopio R; Dei Cas L
Int J Cardiol; 2005 Dec; 105(3):337-9. PubMed ID: 15985302
[TBL] [Abstract][Full Text] [Related]
13. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].
Makai A; Rudas L; Liszkai G; Fazekas T
Orv Hetil; 2003 Feb; 144(5):241-7. PubMed ID: 12647553
[TBL] [Abstract][Full Text] [Related]
14. Torsades de pointes with a severely prolonged QT interval induced by an initial low dose sotalol intake.
Yalta K; Turgut O; Yilmaz A; Yilmaz MB; Kendirlioglu O; Karadas F
Int J Cardiol; 2007 Apr; 116(3):e95-7. PubMed ID: 17126428
[TBL] [Abstract][Full Text] [Related]
15. "Torsade de pointes" in patients with structural heart disease and atrial fibrillation treated with amiodarone, beta-blockers, and digitalis.
Schrickel JW; Schwab JO; Yang A; Bitzen A; Lüderitz B; Lewalter T
Pacing Clin Electrophysiol; 2006 Apr; 29(4):363-6. PubMed ID: 16650263
[TBL] [Abstract][Full Text] [Related]
16. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR
J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331
[TBL] [Abstract][Full Text] [Related]
17. Torsade de pointes with sotalol overdose treated successfully with lidocaine.
Assimes TL; Malcolm I
Can J Cardiol; 1998 May; 14(5):753-6. PubMed ID: 9627533
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
Kühlkamp V; Mermi J; Mewis C; Seipel L
J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
[TBL] [Abstract][Full Text] [Related]
19. QT variability during initial exposure to sotalol: experience based on a large electronic medical record.
Weeke P; Delaney J; Mosley JD; Wells Q; Van Driest S; Norris K; Kucera G; Stubblefield T; Roden DM
Europace; 2013 Dec; 15(12):1791-7. PubMed ID: 23787903
[TBL] [Abstract][Full Text] [Related]
20. Sotalol unmasks susceptibility to drug-induced long QT syndrome and torsades de pointes.
Letsas KP; Efremidis M; Sideris A
Int J Cardiol; 2008 Mar; 124(3):366-7; author reply 368-9. PubMed ID: 17400314
[No Abstract] [Full Text] [Related]
[Next] [New Search]
